

Enrollment

Assessed for eligibility (n=72)

Excluded (n=11)

- ◆ Not meeting inclusion criteria (n=3)
- ◆ Declined to participate (n=8)

Randomized (n=61)

Allocation

Allocated to royal jelly (n=31)
17 Male, 14 Female

Allocated to placebo (n=30)
17 Male, 13 Female

Follow-Up

Lost to follow-up (nonattendance to the final
checkup) (n=1)

Discontinued intervention (adverse effects)
(n=3)

Lost to follow-up (nonattendance to the final
checkup) (n=4)

Discontinued intervention (adverse effects)
(n=5)

Analysis

Analysed (n=30)
15 Male, 11 Female

Analysed (n=26)
16 Male, 14 Female